Document is current

Article History

Received: 11 December 2019

Accepted: 17 June 2020

First Online: 26 June 2020

Ethics approval and consent to participate

: The INFORM study has been approved by the ethic committees of all 18 participating sites: UnorderedList removed

: Not applicable.

: FMT and JP are members of the editorial board of BMC Infectious Diseases. MCN has received grant funding from AstraZeneca. JP has received consulting/speaker fees/honoraria from AbbVie, Seegene Canada and Cepheid, and research grant funding outside of the current work from AbbVie, BD Diagnostics, AstraZeneca, Sanofi Pasteur, Hoffmann-La Roche and Janssen Pharmaceutical. LJB has not received personal fees or other personal benefits. UMCU has received funding from Abbvie, AstraZeneca, Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership IMI-funded RESCEU project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in the INFORM study sponsored by AstraZeneca. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015 to 2017. UMCU received minor funding for consultation and invited lectures by AbbVie, AstraZeneca, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer, Janssen. LJB is the founding chairman of the ReSViNET Foundation. Nirsevimab development is jointly funded by AstraZeneca and Sanofi Pasteur.